634. Myeloproliferative Syndromes: Clinical: New Therapies and JAKi-based Combinations for Myelofibrosis

Watch Session

51 A Phase 2 Study of the LSD1 Inhibitor IMG7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Abdulraheem Yacoub, Kristen M. Pettit, Terrence J Bradley, et al.

Authors Conclusion from the Abstract: This is the first clinical study of an LSD1 inhibitor in patients with MF. Once-daily IMG-7289 as monotherapy was well-tolerated among patients with advanced MF with limited treatment options. With dose optimization, IMG-7289 improved symptom burdens and reduced spleen volume without safety signals. Additionally, improvements in IL-8 levels, fibrosis scores, anemia, and VAF have been observed.

The study is active and remains open for enrollment in the US, UK, EU and Asia.

Naveen Pemmaraju, Jacqueline S. Garcia, Jalaja Potluri, et al.

Authors Conclusion from the Abstract: Pts with MF previously treated with Rux who then receive Nav plus Rux in combination achieved clinically meaningful SVR, TSS improvement, reduction in BMF, and driver gene VAF reductions independent of HMR mutations and the total number of genes mutated. Ongoing cytokine analyses suggest that the combination of Nav plus Rux may have a role in modulating key cytokines implicated in TSS improvement in pts with MF with suboptimal response to Rux alone.

John Mascarenhas, Rami Komrokji, Michele Cavo, et al.

Authors Conclusion from the Abstract: These data show dose-related improvement in OS with imetelstat in pts who are R/R to JAKi. The potential survival benefit observed with imetelstat was supported by the trend of correlation with other clinical benefits and warrants further clinical study.

Srdan Verstovsek, Miklos Egyed, Ewa Lech-Marańda, et al.

Authors Conclusion from the Abstract: In conclusion, further analyses of data from the 550 JAKi-naïve and previously JAKi-treated patients with MF who received MMB in RT and/or ET show robust long-term survival, sustained efficacy and durability of dosing consistent with MMB’s differentiated pharmacological profile. These data demonstrate MMB’s potential ability to durably address the unmet needs of patients with intermediate/high risk MF.

John Mascarenhas, Claire Harrison, Andrea Patriarca, et al.

Authors Conclusion from the Abstract: CPI-0610 + rux combination is generally well-tolerated in JAKi-treatment-naïve MF pts. The preliminary data demonstrate the potential for the combination treatment to provide enhanced efficacy as evidenced by higher SVR35 and TSS50 rates at wk 24 compared with historical data from pivotal Ph3 studies. Overall, the data suggest that the addition of CPI-0610 to rux is potentially synergistic in JAKi-naïve MF pts.

Srdan Verstovsek, John Mascarenhas, Marina Kremyanskaya, et al.

Authors Conclusion from the Abstract: Early clinical data indicate that CPI-0610 as “add-on” to rux is generally well tolerated. The combination therapy provided clinical benefits in most TD pts as assessed by conversion to TI, SVR, and symptomatic responses. SVR and symptomatic benefit were also observed in non-TD patients.